Predict your next investment

HEALTHCARE | Drug Development
promedior.com

See what CB Insights has to offer

Founded Year

2006

Stage

Acquired | Acquired

Total Raised

$64.4M

Valuation

$0000 

About Promedior

Promedior is a clinical stage immunotherapy company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis occurs when healthy tissue is replaced with excessive scar tissue, compromising function and ultimately leading to organ failure. Fibrosis is a common feature of several rare diseases as well as more prevalent illnesses such as age related macular degeneration, diabetic nephropathy, nonalcoholic steatohepatitis (NASH), and several types of solid tumors. On November 15, 2019, Promedior was acquired by Roche at a valuation between $390-1390M.

Promedior Headquarter Location

81 Hartwell Ave

Lexington, Massachusetts, 02421,

United States

781-538-4200

Latest Promedior News

Global Myeloproliferative Neoplasm Drugs Market to Surpass US$ 10,966.8 Million by 2027, Says Coherent Market Insights (CMI)

Mar 4, 2021

Search jobs 04-Mar-2021 Global Myeloproliferative Neoplasm Drugs Market to Surpass US$ 10,966.8 Million by 2027, Says Coherent Market Insights (CMI) SEATTLE--(BUSINESS WIRE)-- #DemethylationAgents --According to Coherent Market Insights, the global myeloproliferative neoplasm drugs market is estimated to be valued at US$ 8,379.5 million in 2020 and is expected to exhibit a CAGR of 3.9% over the forecast period (2020-2027). Key Trends and Analysis: The increasing incidence of myeloproliferative neoplasm is expected to drive growth of the global myeloproliferative neoplasm drugs market over the forecast period. According to the National Organization for Rare Disorders (NORD) 2020, men are more likely to be affected than women with polycythemia vera and this disorder is expected to affect around two people per 100,000 in the general population globally. Moreover, the increasing number of pipeline products for the treatment of myeloproliferative neoplasm is expected to fuel growth of the global myeloproliferative neoplasm drugs market in the near future. For instance, on January 7, 2021, PharmaEssentia Corporation, a company focusing on research and development in biopharmaceutical industry, announced the initiation of investigational study phase 3 pivotal clinical trial of SURPASS ET, [Ropeginterferon Alfa-2b (P1101)]. SURPASS ET is a novel mono-pegylated proline interferon under evaluation for the treatment of the essential thrombocythemia (ET) type of myeloproliferative neoplasm (MPNs). Among regions, North America is expected to register highest growth rate, owing to increasing number of pipeline products for the treatment of myeloproliferative neoplasm. For instance, in December 2020, AbbVie Inc. announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial, evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA/VENCLYXTO (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), during an oral presentation session at the virtual 2020 American Society of Hematology (ASH) Annual Meeting. Request Sample Copy of this Research Report @ Key Market Takeaways: The global myeloproliferative neoplasm drugs market is expected to exhibit a CAGR of 3.9% over the forecast period, as key players are focusing on strategies such as mergers and acquisitions in order to strengthen their position in the market. For Instance, in February 2020, F. Hoffmann-La Roche AG completely acquired Promedior, Inc., a clinical stage biotechnology company. As a result of this acquisition, F. Hoffmann-La Roche AG would obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, including PRM-151. Competitive Landscape: Key players operating in the global myeloproliferative neoplasm drugs market include Novartis International AG, PharmaEssentia Corporation, Bristol - Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc., CTI BioPharma Corp., Imago BioSciences, AbbVie Inc., and Constellation Pharmaceuticals Buy-Now this Research Report for detailed market insights @ Demethylation Agents

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Promedior

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Promedior in 1 CB Insights research brief, most recently on Nov 18, 2019.

Expert Collections containing Promedior

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Promedior is included in 4 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

D

Diabetes

1,750 items

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Promedior Patents

Promedior has filed 16 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Autoimmune diseases
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/8/2014

6/1/2021

Antineoplastic drugs, Experimental cancer drugs, Monoclonal antibodies, Alkylating antineoplastic agents, Organochlorides

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/8/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/1/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Antineoplastic drugs, Experimental cancer drugs, Monoclonal antibodies, Alkylating antineoplastic agents, Organochlorides

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.